Frontiers in Bioengineering and Biotechnology | |
Resveratrol-Loaded TPGS-Resveratrol-Solid Lipid Nanoparticles for Multidrug-Resistant Therapy of Breast Cancer: In Vivo and In Vitro Study | |
Rongjie Li1  Youjing Wang1  Wei Peng1  Shiwen Zhang1  Chengxu Yue1  Wenrui Wang1  Hui Zhang1  Shumin Cheng1  Yang Xu1  Han Zhang1  Changjie Chen2  Qingling Yang2  Xinyu Wei2  Mengyang Zhou3  | |
[1] Anhui Province Key Laboratory of Translational Cancer Research, Department of Biotechnology, Bengbu Medical College, Anhui, China;Department of Biochemistry, School of Laboratory Medicine Bengbu Medical College, Anhui, China;Department of Life Sciences, Anhui Medical University, Anhui, China; | |
关键词: multidrug resistance; drug delivery; resveratrol; solid lipid nanoparticle; breast cancer; | |
DOI : 10.3389/fbioe.2021.762489 | |
来源: DOAJ |
【 摘 要 】
Multidrug resistance (MDR) is a serious problem during cancer therapy. The purpose of the present study was to formulate D-α-Tocopheryl polyethylene glycol 1000 succinate-resveratrol-solid lipid nanoparticles (TPGS-Res-SLNs) to improve its therapeutic efficacy against breast cancer. In this study, the solvent injection method was used to prepare the TPGS-Res-SLNs. It was found that the TPGS-Res-SLNs exhibited zeta potential and drug-loading of −25.6 ± 1.3 mV and 32.4 ± 2.6%, respectively. Therefore, it was evident that the TPGS-Res-SLNs can increase cellular uptake of chemotherapeutic drugs, induce mitochondrial dysfunction, and augment tumor treatment efficiency by inducing apoptosis. Moreover, it was found that SKBR3/PR cells treated with TPGS-Res-SLNs exhibited significant inhibition of cell migration and invasion, as compared with free resveratrol. In addition, results from in vivo SKBR3/PR xenograft tumor models revealed that TPGS-Res-SLNs has better efficacy in promoting apoptosis of tumor cells owing to high therapeutic outcomes on tumors when compared with the efficacy of free resveratrol. In conclusion, the findings of the present study indicate significant potential for use of TPGS-Res-SLNs as an efficient drug delivery vehicle to overcome drug resistance in breast cancer therapy.
【 授权许可】
Unknown